Parallax Volatility Advisers, L.P. Clovis Oncology, Inc. Transaction History

Parallax Volatility Advisers, L.P.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.63 - $2.96 $54,394 - $255,566	-86,340 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$1.43 - $3.14 $68,654 - $150,751	48,010 Added 125.25%	86,340 $174,000
Q4 2021 Feb 14, 2022	SELL	$2.7 - $4.76 $7,271 - $12,818	-2,693 Reduced 6.56%	38,330 $104,000
Q3 2021 Nov 15, 2021	SELL	$4.06 - $5.8 $27,453 - $39,219	-6,762 Reduced 14.15%	41,023 $183,000
Q2 2021 Aug 16, 2021	SELL	$5.02 - $7.05 $1.09 Million - $1.53 Million	-216,535 Reduced 81.92%	47,785 $277,000
Q3 2019 Nov 14, 2019	BUY	$3.93 - $15.35 $762,533 - $2.98 Million	194,029 Added 276.04%	264,320 $1.04 Million
Q4 2018 Feb 14, 2019	BUY	$11.63 - $32.67 $563,508 - $1.58 Million	48,453 Added 221.87%	70,291 $1.26 Million
Q3 2018 Nov 14, 2018	BUY	$29.37 - $49.48 $641,382 - $1.08 Million	21,838 New	21,838 $641,000
Q1 2018 May 15, 2018	SELL	$50.12 - $67.72 $404,318 - $546,297	-8,067 Closed	0 $0
Q4 2017 Feb 14, 2018	SELL	$57.69 - $84.58 $928,520 - $1.36 Million	-16,095 Reduced 66.61%	8,067 $549,000
Q3 2017 Nov 14, 2017	BUY	$67.17 - $84.81 $1.62 Million - $2.05 Million	24,162	24,162 $1.99 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.